Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen

Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)

SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

Time frame: Posttreatment Week 4

Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

SVR 24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

Time frame: Posttreatment Week 24

Percentage of Participants With HCV RNA < LLOQ at Week 1

Time frame: Week 1

Percentage of Participants With HCV RNA < LLOQ at Week 2

Time frame: Week 2

Percentage of Participants With HCV RNA < LLOQ at Week 3

Time frame: Week 3

Percentage of Participants With HCV RNA < LLOQ at Week 4

Time frame: Week 4

Percentage of Participants With HCV RNA < LLOQ at Week 5

Time frame: Week 5

Percentage of Participants With HCV RNA < LLOQ at Week 6

Time frame: Week 6

Percentage of Participants With HCV RNA < LLOQ at Week 8

Time frame: Week 8

Percentage of Participants With HCV RNA < LLOQ at Week 10

Time frame: Week 10

Percentage of Participants With HCV RNA < LLOQ at Week 12

Time frame: Week 12

Percentage of Participants With HCV RNA < LLOQ at Week 16

Time frame: Week 16

Percentage of Participants With HCV RNA < LLOQ at Week 20

Time frame: Week 20

Percentage of Participants With HCV RNA < LLOQ at Week 24

Time frame: Week 24

Change From Baseline in HCV RNA at Week 1

Time frame: Baseline; Week 1

Change From Baseline in HCV RNA at Week 2

Time frame: Baseline; Week 2

Change From Baseline in HCV RNA at Week 3

Time frame: Baseline; Week 3

Change From Baseline in HCV RNA at Week 4

Time frame: Baseline; Week 4

Change From Baseline in HCV RNA at Week 5

Time frame: Baseline; Week 5

Change From Baseline in HCV RNA at Week 6

Time frame: Baseline; Week 6

Change From Baseline in HCV RNA at Week 8

Time frame: Baseline; Week 8

Change From Baseline in HCV RNA at Week 10

Time frame: Baseline; Week 10

Change From Baseline in HCV RNA at Week 12

Time frame: Baseline; Week 12

Change From Baseline in HCV RNA at Week 16

Time frame: Baseline; Week 16

Change From Baseline in HCV RNA at Week 20

Time frame: Baseline; Week 20

Change From Baseline in HCV RNA at Week 24

Time frame: Baseline; Week 24

Percentage of Participants With Overall Virologic Failure

Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

Time frame: Up to Posttreatment Week 24